AstraZeneca Reports Phase 2 Results for Savolitinib in MET-Driven Renal Cell Carcinoma

AstraZeneca today announced Phase 2 trial results for savolitinib in patients with MET-driven papillary renal cell carcinoma. The trial demonstrated an objective response rate of 27% in patients with MET-driven disease, with a median progression-free survival of 6.2 months. These results support further development of savolitinib in MET-driven renal cell carcinoma.